• Curanex shareholders authorized a reverse stock split of common stock, with the ratio set within a 1-for-10 to 1-for-50 range.
• The board would select the final split ratio, with the move aimed at lifting the per-share trading price.
• Shareholders also authorized a 2026 equity incentive plan reserving up to 5,700,000 common shares for awards to employees, directors, consultants.
• The plan includes an annual share reserve increase of up to 4% of outstanding shares, subject to administrator discretion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curanex Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-029388), on June 18, 2026, and is solely responsible for the information contained therein.